Global Ablation Devices Market Size

Ablation Devices Market Analysis

The market for ablation devices is expected to grow at a CAGR of 10.4% over the next few years.

The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. For instance, as per the article published in November 2022 in PubMed, during the early stages of the COVID-19 pandemic, catheter ablation (CA) significantly decreased before gradually increasing to pre-COVID-19 levels. Due to the suspension of all non-urgent elective surgical operations during the COVID-19 pandemic, the number of ablation surgeries performed during the period is very low compared to that of the previous year. However, the market is anticipated to witness growth in the coming years due to the rise in the prevalence of chronic diseases and an increase in product sales.

Major chronic diseases such as cancer, cardiovascular diseases, and other ophthalmologic, gynecological, and urological diseases are on the rise all over the world, which is contributing to the growth of the ablation devices market. With increasing risks, there are also effective surgical therapies that lead to the efficient treatment of patients suffering from chronic illnesses. Furthermore, the increasing number of factors contributing to the rise in chronic disease is increasing the market share for ablation devices.For instance, as per the American Cancer Society, the number of people estimated to be diagnosed with cancer is likely to be 1.9 million in 2022 in the United States. Also, according to the International Diabetes Federation's Diabetes Atlas, Tenth Edition, for 2021, in 2021, around 537 million adults all over the world were found to have diabetes, with the numbers projected to grow to 643 million by 2030 and 783 million by 2045. In individuals with diabetes mellitus (DM), catheter ablation of atrial fibrillation (AF) appears to be a safe therapy that considerably lowers symptom load. Additionally, as per the Elective Surgery Activity Data published by AIHW, the number of patients added for elective surgery in 2020-2021 (893,200) was a 6.6% increase in the number of additions from the previous year. Hence, with the rise in the number of chronic diseases coupled with an increase in elective surgery cases, the market studied is expected to grow over the forecast period.

Several research and development studies focusing on innovative ablation devices are also contributing to the growth of the blood flow device measurement market. For instance, in May 2021, Acutus Medical initiated a prospective, multi-center, non-randomized global clinical study designed to demonstrate the safety and performance of the AcQBlate Force Sensing System. The AcQBlate Force Sensing System is a complete and differentiated solution for the electrophysiologic mapping and radiofrequency ablation of cardiac arrhythmias. The study focuses on the catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein and is expected to be completed by January 2024. The increasing research in the development of ablation devices is expected to boost the growth of the ablation devices market in the forecast period.

The increasing developments made among the key players in the ablation segment are also contributing to the growth of the market. For instance, in November 2021, Hologic, Inc., launched the NovaSure V5 global endometrial ablation (GEA) device, the most studied and trusted endometrial ablation procedure in the United States. The rise in the research and development of such devices is expected to boost market growth.

Thus, due to the rise in chronic diseases, increase in product launches, and research associated with ablation devices, the studied market is anticipated to witness growth over the forecast period. However, the high cost of the devices and the strict regulations, coupled with the risk associated with the ablation procedures, are likely to hinder the market's growth.